Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Current multiple myeloma treatment strategies with novel agents: a European perspective is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1634/THEONCOLOGIST.2009-0203
P932PMC publication ID3227886
P698PubMed publication ID20086168
P5875ResearchGate publication ID41088269

P50authorAntonio PalumboQ87013105
Joan BladéQ87885218
Heinz LudwigQ89444139
Torben PlesnerQ92735832
Sonja ZweegmanQ92858507
Mario BoccadoroQ98568600
Pia SondergeldQ114442074
Jamie D CavenaghQ114442098
Nicolas KettererQ117252291
Johannes DrachQ123476050
Urs HessQ123476051
Martin KropffQ123476055
Hartmut GoldschmidtQ23061917
Hermann EinseleQ1610986
Jean-Luc HarousseauQ3167165
Jesús San MiguelQ5930658
Athanasios DimopoulosQ26338766
Ofer ShpilbergQ28052929
Meral BeksacQ57078421
Michele CavoQ57233657
Gareth J. MorganQ61996585
Larisa MendeleevaQ63641376
Pieter SonneveldQ73546936
Thierry FaconQ85789960
P2860cites workMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialQ28252396
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialQ30433139
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaQ33375805
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionQ33376149
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapyQ33376181
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftmentQ33376918
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaQ33377526
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.Q33378895
Expanding role of bortezomib in multiple myeloma: nursing implicationsQ33379476
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaQ33380816
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access programQ33382175
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).Q33383048
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event resultsQ33384298
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaQ33384668
Antitumor activity of thalidomide in refractory multiple myelomaQ33880642
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myelomaQ34195428
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaQ34401962
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaQ34585268
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelineQ34603644
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Q34604658
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA sQ34613164
Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaQ34815786
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma FoundationQ35606328
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).Q35803516
Improved survival in multiple myeloma and the impact of novel therapiesQ36478461
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myelomaQ36765107
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesQ36941047
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myelomaQ37007113
Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaQ37038414
Thalidomide for treatment of multiple myeloma: 10 years laterQ37075738
Individualizing treatment of patients with myeloma in the era of novel agents.Q37143728
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasoneQ37268930
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapyQ37353007
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaQ37375819
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkQ37493951
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myelomaQ37523265
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensQ37533983
The role of complete response in multiple myelomaQ37564828
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myelomaQ40201943
VAD-based regimens as primary treatment for multiple myelomaQ41924796
Thalidomide maintenance in multiple myeloma: certainties and controversiesQ43273410
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myelomaQ43282882
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaQ43726973
The role of second autografts in the management of myeloma at first relapse.Q44204181
An update of the management of multiple myeloma: the changing landscapeQ44248081
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureQ44620764
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysisQ44738504
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failureQ44971622
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal functionQ45250378
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.Q46006794
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.Q46068547
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedureQ46094234
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survivalQ46253134
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myelomaQ46291462
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyQ46423653
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.Q46573449
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.Q46793597
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 studyQ46804697
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaQ46827259
Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?Q46859906
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisQ46936772
Recent major improvement in long-term survival of younger patients with multiple myelomaQ46977305
Thalidomide and hematopoietic-cell transplantation for multiple myelomaQ46981475
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialQ46985882
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?Q48011772
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.Q53589005
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyQ58050810
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du MyélomeQ71123629
Tubular NF-kappaB and AP-1 activation in human proteinuric renal diseaseQ74566827
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patientsQ78102288
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsQ79345406
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseQ79420311
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yieldQ80008483
Maintenance therapy with thalidomide improves survival in patients with multiple myelomaQ80011690
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasoneQ80667422
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myelomaQ80764931
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialQ80776203
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myelomaQ80984355
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaQ81251723
Prolonged overall survival with second on-demand autologous transplant in multiple myelomaQ83300465
P433issue1
P921main subjectthalidomideQ203174
boronic acidQ335768
multiple myelomaQ467635
antineoplasticQ2853144
pyrazineQ47463389
P1104number of pages20
P304page(s)6-25
P577publication date2010-01-19
P1433published inOncologistQ2122327
P1476titleCurrent multiple myeloma treatment strategies with novel agents: a European perspective
P478volume15

Reverse relations

cites work (P2860)
Q38139989An old drug with a new future: bendamustine in multiple myeloma.
Q42184785Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
Q37197900BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
Q55058300Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Q33874209Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone
Q55515927Characteristics and outcomes of patients with multiple myeloma : Data from a developing country.
Q90266389Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations?
Q83979410Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
Q26795696Clinical characteristics of patients with relapsed multiple myeloma
Q37761370Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.
Q38271032Current treatment landscape for relapsed and/or refractory multiple myeloma
Q31094748Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
Q36254820Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011.
Q55383806Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma.
Q38037600Emerging biological insights and novel treatment strategies in multiple myeloma
Q35989943European perspective on multiple myeloma treatment strategies: update following recent congresses
Q85084727Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents
Q55310900Impaired efferocytosis by monocytes in multiple myeloma.
Q38199171Is high cut-off hemodialysis effective in myeloma kidney?
Q37978343Management of myeloma-associated renal dysfunction in the era of novel therapies
Q38888980Modulation of cereblon levels by anti-myeloma agents.
Q37858327Multiple myeloma treatment strategies with novel agents in 2011: a European perspective
Q34420112Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
Q38108391Perspectives in the treatment of multiple myeloma
Q33938595Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo
Q30802505Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data
Q39583526Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
Q43115406Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma
Q30501430Shear flow-induced formation of tubular cell protrusions in multiple myeloma cells.
Q40621650Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity
Q40647620Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
Q34081748Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines
Q34227679The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.
Q30538040Time-dependent endpoints as predictors of overall survival in multiple myeloma
Q92930272Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs

Search more.